Photodynamic versus white light-guided treatment of non-muscle invasive bladder cancer: a study protocol for a randomised trial of clinical and cost-effectiveness.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
03 09 2019
Historique:
entrez: 5 9 2019
pubmed: 5 9 2019
medline: 2 10 2020
Statut: epublish

Résumé

Bladder cancer is the most frequently occurring tumour of the urinary system. Ta, T1 tumours and carcinoma in situ (CIS) are grouped as non-muscle invasive bladder cancer (NMIBC), which can be effectively treated by transurethral resection of bladder tumour (TURBT). There are limitations to the visualisation of tumours with conventional TURBT using white light illumination within the bladder. Incomplete resections occur from the failure to identify satellite lesions or the full extent of the tumour leading to recurrence and potential risk of disease progression. To improve complete resection, photodynamic diagnosis (PDD) has been proposed as a method that can enhance tumour detection and guide resection. The objective of the current research is to determine whether PDD-guided TURBT is better than conventional white light surgery and whether it is cost-effective. PHOTO is a pragmatic multicentre randomised controlled trial (open parallel group, non-masked and superiority trial) comparing the intervention of PDD-guided TURBT with standard white light resection in newly diagnosed intermediate and high risk NMIBC within the UK National Health Service setting. Clinical effectiveness is measured with time to recurrence. Cost-effectiveness is assessed within trial via the calculation of incremental cost per recurrence avoided and incremental cost per quality-adjusted life per year gained over 3 years and over long term through a modelling exercise over patients' lifetime. Formal ethics review was undertaken with a favourable opinion, in line with UK regulatory procedures (REC reference number: 14/NE/1062). If reductions in time to recurrence is associated with long-term patient benefits, the cost-effectiveness evaluation will provide further evidence to inform adoption of the technology. Findings will be shared in lay media such as patient and charity forums and will be presented at key meetings and published in academic literature.Trial registration number ISRCTN84013636.

Identifiants

pubmed: 31481549
pii: bmjopen-2018-022268
doi: 10.1136/bmjopen-2018-022268
pmc: PMC6731798
doi:

Substances chimiques

Photosensitizing Agents 0

Banques de données

ISRCTN
['ISRCTN84013636']

Types de publication

Clinical Trial Protocol Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e022268

Subventions

Organisme : Department of Health
ID : 11/142/02
Pays : United Kingdom
Organisme : Chief Scientist Office
ID : HSRU1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K02325X/1
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Eur Urol. 2002 May;41(5):523-31
pubmed: 12074794
Qual Life Res. 2003 Sep;12(6):675-88
pubmed: 14516177
BJU Int. 2005 Jan;95(1):59-63
pubmed: 15638895
Urology. 2005 Feb;65(2):290-4
pubmed: 15708040
J Urol. 2005 Apr;173(4):1318-22
pubmed: 15758789
Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7
pubmed: 16442208
BJU Int. 2008 May;101(9):1106-10
pubmed: 17888042
Pharmacoeconomics. 2008;26(9):745-51
pubmed: 18767895
Ann R Coll Surg Engl. 2010 Sep;92(6):519-24
pubmed: 20522307
Int J Technol Assess Health Care. 2011 Jan;27(1):3-10
pubmed: 21262078
Eur Urol. 2013 Oct;64(4):624-38
pubmed: 23906669
Nature. 2014 Mar 20;507(7492):315-22
pubmed: 24476821
Int J Mol Sci. 2014 Dec 22;15(12):23897-908
pubmed: 25535079
Urol Clin North Am. 2015 May;42(2):235-52, ix
pubmed: 25882565
Eur Urol. 2016 Mar;69(3):438-47
pubmed: 26508308
Eur Urol. 2017 Mar;71(3):447-461
pubmed: 27324428
Am J Surg Pathol. 1998 Dec;22(12):1435-48
pubmed: 9850170

Auteurs

Zafer Tandogdu (Z)

Urology, Northern Institute for Cancer Research, Newcastle upon Tyne, UK.

Rebecca Lewis (R)

Urology and Head and Neck Trials Team, Institute of Cancer Research, London, UK.

Anne Duncan (A)

Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, UK.

Steven Penegar (S)

Urology and Head and Neck Trials Team, Institute of Cancer Research, London, UK.

Alison McDonald (A)

Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, UK.

Luke Vale (L)

Health Economics Group, Institute of Health and Society, Newcastle University, Newcastle, UK.

Jing Shen (J)

Health Economics Group, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK.

John D Kelly (JD)

Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK.

Robert Pickard (R)

Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.

James N Dow (J)

Department of Surgery, University of Aberdeen, Aberdeen, UK.

Craig Ramsay (C)

Health Service Research Unit, University of Aberdeen, Aberdeen, UK.

Hugh Mostafid (H)

Urology, Hampshire Hospitals NHS Foundation Trust, Winchester, UK.

Paramananthan Mariappan (P)

Department of Urology, Western General Hospital, Edinburgh, UK.

Ghulam Nabi (G)

Department of Medicine, University of Dundee, Dundee, UK.

Joanne Creswell (J)

Urology, South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK.

Henry Lazarowicz (H)

Urology, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.

John McGrath (J)

Department of Urology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.

Ernest Taylor (E)

Trial Management Group, PHOTO Trial, UK.

Emma Clark (E)

Urology, Northern Institute for Cancer Research, Newcastle upon Tyne, UK.

Graeme Maclennan (G)

Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, UK.

John Norrie (J)

Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh, UK.

Emma Hall (E)

Urology and Head and Neck Trials Team, The Institute of Cancer Research, London, UK.

Rakesh Heer (R)

Urology, Northern Institute for Cancer Research, Newcastle upon Tyne, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH